Efficacy of COVID-19 Booster Vaccines in Patients with Hematologic Malignancies: Experiences in a Real-World Scenario

Background: Two-dose COVID-19 vaccination often results in poor humoral response rates in patients with hematologic malignancies (HMs); yet responses to COVID-19 booster vaccines and the risk of COVID-19 infection post-booster are mostly uncertain. Methods: We included 200 outpatients with HMs and p...

Full description

Bibliographic Details
Main Authors: Carolin Krekeler, Lea Reitnauer, Ulrike Bacher, Cyrus Khandanpour, Leander Steger, Göran Ramin Boeckel, Justine Klosner, Phil-Robin Tepasse, Marcel Kemper, Marc Tim Hennies, Rolf Mesters, Matthias Stelljes, Norbert Schmitz, Andrea Kerkhoff, Christoph Schliemann, Jan-Henrik Mikesch, Nicole Schmidt, Georg Lenz, Annalen Bleckmann, Evgenii Shumilov
Format: Article
Language:English
Published: MDPI AG 2022-11-01
Series:Cancers
Subjects:
Online Access:https://www.mdpi.com/2072-6694/14/22/5512